How Much Does Vyleesi (Bremelanotide) Cost in Delaware in 2026?

Brand-Name Vyleesi Pricing in Delaware

The manufacturer list price for Vyleesi sits at $1,200 per month, and Delaware retail pharmacies reflect that number almost exactly at the cash-pay counter. Each carton contains a set of single-dose, prefilled auto-injectors designed for subcutaneous self-administration at least 45 minutes before anticipated sexual activity. The FDA-approved labeling caps use at one dose per 24 hours and no more than eight doses per calendar month.

That $1,200 figure does not account for any copay assistance, insurance negotiation, or pharmacy-level discounting. It represents what a patient without coverage would pay at chains like CVS, Walgreens, or Rite Aid locations in Wilmington, Dover, or Newark. Specialty pharmacies that stock Vyleesi may quote marginally different prices depending on acquisition cost, but the variation across Delaware stays narrow. The drug's niche indication (premenopausal HSDD) and limited competition keep downward pricing pressure minimal.

Bremelanotide is a melanocortin-4 receptor agonist. It was approved by the FDA in June 2019 based on two Phase 3 trials. The RECONNECT trials (N=1,247 combined) demonstrated statistically significant improvements in both desire and distress scores compared to placebo over 24 weeks. Specifically, 34.9% of bremelanotide-treated patients achieved a meaningful increase in sexual desire versus 18.5% on placebo. These efficacy data support the clinical rationale for coverage, though access remains a separate challenge.

Delaware Medicaid Coverage for Vyleesi

Delaware Medicaid does cover Vyleesi. Prior authorization is required. The prescriber must document that the patient meets diagnostic criteria for HSDD in accordance with DSM-5, that the condition is not attributable to a co-existing medical or psychiatric condition, substance use, or relationship factors, and that the patient is premenopausal. Medicaid managed care organizations in Delaware (such as AmeriHealth Caritas Delaware and Highmark Health Options) follow similar PA criteria, though each MCO may layer on its own step-therapy or clinical documentation requirements.

PA approval timelines in Delaware typically run 3 to 5 business days for standard requests. Urgent or expedited requests can be processed within 24 hours when clinically justified. If denied, patients have the right to appeal, and the prescriber can submit a peer-to-peer review.

A practical consideration: because Vyleesi is dosed as needed rather than daily, the actual monthly cost to the payer depends on usage frequency. A patient who uses four doses per month consumes roughly half of the maximum allowable monthly supply, which some MCOs factor into their utilization management models.

Compounded Bremelanotide in Delaware: Legality and Cost

Compounded bremelanotide is available in Delaware through licensed 503A compounding pharmacies. This is legal. Under federal law (the Drug Quality and Security Act, Section 503A), a compounding pharmacy may prepare patient-specific formulations of bremelanotide based on a valid prescription, provided the pharmacy holds appropriate state licensure and the compounded product is not a copy of a commercially available drug in a form that is essentially equivalent.

The cost difference is dramatic. Where brand-name Vyleesi runs $1,200 per month, compounded bremelanotide from a 503A pharmacy typically costs around $140 per month. That represents an 88% reduction.

Compounded formulations may differ from the brand product in concentration, delivery device, and inactive ingredients. They do not carry FDA approval, they are not subject to the same bioequivalence testing, and they are not interchangeable with Vyleesi at the pharmacy counter. Patients considering this route should discuss the tradeoffs with their prescriber. The FDA's guidance on compounding outlines the regulatory boundaries.

Delaware does not impose additional state-level restrictions beyond federal 503A requirements. The Delaware Board of Pharmacy oversees compounding pharmacies operating within the state, and out-of-state 503A pharmacies shipping into Delaware must hold a non-resident pharmacy license. Patients in Sussex County or Kent County who lack a local compounding pharmacy can legally receive shipped compounded bremelanotide from a licensed out-of-state 503A facility.

Insurance Coverage Beyond Medicaid

Commercial insurance coverage for Vyleesi in Delaware varies by plan and carrier. Highmark Blue Cross Blue Shield of Delaware, Aetna, and Cigna all have formulary entries for Vyleesi, but each requires prior authorization. Some plans classify it as a specialty-tier drug, placing it in Tier 4 or Tier 5, which typically carries a coinsurance structure (25% to 40%) rather than a flat copay. On a $1,200 list price, that translates to $300 to $480 out of pocket per month before any manufacturer assistance.

Self-insured employer plans (ERISA plans) make independent formulary decisions. Some exclude Vyleesi entirely. Others cover it with step therapy requiring documented failure of off-label alternatives (such as flibanserin, marketed as Addyi) before approving bremelanotide.

For patients on marketplace (ACA) plans purchased through the Delaware Health Insurance Marketplace, coverage depends on whether the specific plan's formulary includes Vyleesi. The ACA does not mandate coverage of any particular drug by name. It requires coverage of at least one drug per United States Pharmacopeia category. HSDD treatments do not form a standalone USP class, so plans have discretion.

The Veterans Health Administration (VA) and TRICARE may cover Vyleesi for eligible beneficiaries, again subject to prior authorization and formulary restrictions. Delaware has a sizable veteran population, and the Wilmington VA Medical Center pharmacy can process Vyleesi prescriptions when criteria are met.

According to real-world data, fewer than 30% of commercially insured women with HSDD who are prescribed Vyleesi successfully fill the prescription at their first attempt, a figure consistent with specialty drug access barriers reported in JAMA Network Open. Prior authorization rejections, high cost-sharing, and pharmacy stocking issues all contribute to abandonment.

Telehealth Prescribing in Delaware

Delaware permits telehealth prescribing of Vyleesi. The state's telehealth parity law (Delaware Code Title 18, Section 3571K) requires insurers to cover telehealth-delivered services on the same terms as in-person visits. A prescriber licensed in Delaware can evaluate a patient via synchronous video, diagnose HSDD, and prescribe bremelanotide without an in-person examination, provided the standard of care is met.

This matters for access. Delaware is a small state geographically, but parts of Sussex County are medically underserved. Telehealth eliminates the drive to Wilmington or Dover for a specialist visit. Several national telehealth platforms that focus on women's sexual health now prescribe Vyleesi to Delaware residents after a virtual consultation.

The prescriber must be licensed in Delaware or hold a multi-state license recognized by Delaware. DEA registration is not required for Vyleesi prescriptions because bremelanotide is not a scheduled substance.

How the Palatin Technologies Savings Card Works

Palatin Technologies, the company behind Vyleesi, offers a manufacturer savings card for commercially insured patients. The card can reduce out-of-pocket costs to as low as $0 per fill for eligible patients, though the benefit cap varies by program cycle. Typical savings card structures cover up to $400 to $600 per fill, with the patient responsible for any remainder.

Eligibility criteria are standard for pharma copay cards: the patient must have commercial insurance (not Medicare, Medicaid, or other government-funded coverage), must reside in a state where copay cards are legal, and must fill the prescription at a participating pharmacy. Delaware does not have any state-level copay accumulator or copay maximizer laws that would redirect the savings card value away from the patient's deductible, though individual plan designs may include accumulator adjusters.

To activate the card, patients typically register online through the Vyleesi website or receive an activation code from their prescriber. The card is then processed as a secondary payer at the pharmacy.

For uninsured patients, Palatin has periodically offered a patient assistance program (PAP) that provides Vyleesi at no cost to qualifying individuals below certain income thresholds. Availability of the PAP changes year to year. Patients should contact Palatin directly or ask their prescriber's office to check current program status.

Comparing Your Options: Brand vs. Compounded vs. Insured

The decision between brand-name Vyleesi, compounded bremelanotide, and insurance-covered Vyleesi depends on three variables: coverage status, cost tolerance, and clinical comfort with compounded products.

A patient with commercial insurance and the Palatin savings card may pay $0 to $50 per fill. That is the lowest-friction path. A patient with Delaware Medicaid pays whatever the Medicaid copay structure dictates, which for preferred brand drugs in Delaware is typically $1 to $3 per prescription.

A patient without insurance or with a plan that excludes Vyleesi faces the full $1,200 per month. For that patient, compounded bremelanotide at $140 per month is often the pragmatic choice. The savings are roughly $12,720 per year.

The RECONNECT trial data established the efficacy profile for the branded product specifically. No published head-to-head trial compares brand Vyleesi to compounded bremelanotide. The active ingredient is the same, but the delivery system and pharmacokinetic profile may differ depending on the compounding pharmacy's formulation.

Patients who use Vyleesi infrequently (two or fewer doses per month) may find the per-dose economics more tolerable even at brand pricing, since the effective monthly cost scales with use. At two doses per month, the per-dose cost for brand Vyleesi runs approximately $150, compared to roughly $18 per dose for the compounded version.

Side Effects and Safety Considerations

The FDA labeling for Vyleesi reports the most common adverse reactions as nausea (40%), flushing (20%), injection site reactions (13%), and headache (11%). Nausea is the primary reason patients discontinue treatment. In the RECONNECT trials, 13% of bremelanotide-treated patients stopped due to nausea versus 2% on placebo.

A boxed warning does not apply, but the label carries a specific warning about transient blood pressure increases. Systolic blood pressure rose by an average of 2 to 3 mmHg in clinical trials. Bremelanotide is contraindicated in patients with uncontrolled hypertension or known cardiovascular disease. The label also advises against use in patients taking oral naltrexone due to a potential pharmacokinetic interaction that could reduce naltrexone's efficacy.

Skin hyperpigmentation, particularly of the face, gums, and breasts, occurred in up to 1% of patients in clinical trials. The pigmentation changes may not fully resolve after discontinuation. Delaware prescribers should counsel patients about this possibility, particularly those with darker baseline skin tones who may be more susceptible.

The RECONNECT trials enrolled 1,247 premenopausal women across two studies, with a treatment duration of 24 weeks. Long-term safety data beyond 18 months remain limited. Post-marketing surveillance has not identified new safety signals since the 2019 approval, according to the FDA Adverse Event Reporting System (FAERS).